Osimertinib-Induced Cardiomyopathy
Author:
Publisher
Elsevier BV
Subject
Cardiology and Cardiovascular Medicine
Reference14 articles.
1. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer;Soria;N Engl J Med,2018
2. Osimertinib induced cardio-toxicity: a retrospective review of FDA adverse events reporting system (FAERS);Anand;J Clin Oncol,2019
3. Osimertinib as first-line therapy in advanced NSCLC: a profile of its use;Scott;Drugs Ther Perspect,2018
4. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study;Goss;Lancet Oncol,2016
5. Osimertinib-induced cardiotoxicity;Anand;J Am Coll Cardiol CardioOncol,2019
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. EGFR-TKIs - induced cardiotoxicity in NSCLC: incidence, evaluation, and monitoring;Frontiers in Oncology;2024-06-24
2. QT-Interval Prolongation, Torsades de Pointes, and Heart Failure With EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Systematic Review;Clinical Lung Cancer;2024-06
3. Delayed cardiotoxicity following osimertinib therapy in non-small cell lung cancer: a unique case report;Anti-Cancer Drugs;2024-03-08
4. Osimertinib Related Cardiotoxicity Profile in Patients with Non-Small Cell Lung Cancer and Egfr Mutation;2024
5. Research Progress on the Cardiotoxicity of EGFR-TKIs in Non-Small Cell Lung Cancer;Current Treatment Options in Oncology;2023-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3